Relavent - Revision history

>Chris at 11:30, 21 September 2022

2022-09-21T11:30:56Z

← Older revision		Revision as of 12:30, 21 September 2022
Line 1:		Line 1:
			{{Cover Image\|[[File:Relevant cover image.jpg]]}}

	== Summary<ref name=":0">Source: the company.</ref> ==		== Summary<ref name=":0">Source: the company.</ref> ==
	RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.		RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.

95.149.241.133 at 15:22, 20 August 2022

2022-08-20T15:22:07Z

← Older revision		Revision as of 16:22, 20 August 2022
Line 77:		Line 77:
	[[Category:Thesis]]		[[Category:Thesis]]
	[[Category:Equities]]		[[Category:Equities]]

			__INDEX__

109.180.50.163 at 13:17, 14 August 2022

2022-08-14T13:17:22Z

← Older revision		Revision as of 14:17, 14 August 2022
Line 1:		Line 1:
	~~'''About RELAVENT~~:~~'''~~		== Summary<ref name=":0">Source: the company.</ref> ==

	RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.		RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.

	~~'''RELAVENT vision:'''~~

	To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).		To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).

	Note: Working title during development was JAMVENT.		Note: Working title during development was JAMVENT.

	~~'''Status on current round:'''~~

	Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.		Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.
Line 15:		Line 10:
	<youtube>s9QnM3rjS14</youtube>		<youtube>s9QnM3rjS14</youtube>

	==Investment Interview==		==Investment Interview<ref name=":0" />==

	'''Explain what your venture does.'''		'''Explain what your venture does.'''
Line 78:		Line 73:

	Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.		Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.

			== References and notes ==
	[[Category:Thesis]]		[[Category:Thesis]]
	[[Category:Equities]]		[[Category:Equities]]

109.180.50.163: Undo revision 31263 by 109.180.50.163 (talk)

2022-08-14T13:16:32Z

Undo revision 31263 by 109.180.50.163 (talk)

← Older revision		Revision as of 14:16, 14 August 2022
Line 1:		Line 1:
	~~== Summary ==~~		'''About RELAVENT:'''

	~~'''About RELAVENT:'''~~RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.'''RELAVENT vision:'''To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).Note: Working title during development was JAMVENT.'''Status on current round:'''Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.<youtube>s9QnM3rjS14</youtube>==Investment Interview=='''Explain what your venture does.'''RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. Its operation requires minimal electrical power. RELAVENT can be run with an oxygen concentrator or bottled gases in case of challenges in hospital gas supplies.'''What stage is your business?'''Imperial College Spinout. TRL 4.'''Describe your advisers.'''Liz Hughes (CEO): High sales growth portfolio. Commercial effectiveness specialist, accredited leadership coach. Business growth and turnaround leader. Steve Atkinson (Board Chair): Successful 30-year career in medical devices, entrepreneur, experienced fund raiser, business leader. Multiple successful exits.'''Give an overview of your startup's financing history.'''Grants from Imperial College COVID fund (£60k) and Royal Academy of Engineering (£20k). Departmental support. Used for prototyping, testing and submission to USA FDA for Emergency Use Authorization.'''Explain the ownership structure of your company.'''Imperial-based Founders: van Batenburg-Sherwood, Mathiszig-Lee, Madekurozwa, Moore, Watson, Bonneuil, Frattolin. Imperial College (IP ownership; Founder-Driven Route).'''How many employees do you have?'''2.'''Please provide the name of a lawyer, who will represent you for the upcoming investment round.'''Taylor Wessing, Ross McNaughton.'''How much money are you seeking to raise in the current round?'''£3m.'''Do you have any existing commitments to the current round?'''Family offices tentatively committed for £2m but seeking lead investor.'''Explain why you are raising finance.'''Complete the regulatory-compliant design process (6-9 months). Submit applications for regulatory approval (2-3 months). Clinical testing (2-3 months). Marketing. Distribution.'''Please explain the history of your venture.'''RELAVENT aims to provide reliable ICU-standard ventilators to low income markets where current ventilator technologies are unaffordable. The project was initiated in March 2020 in response to the COVID-19 pandemic, but the market to address diseases such as TB, malaria and influenza is much larger. Within 72 days of project initiation, we had developed a working prototype, tested it to ISO standards and submitted several hundred pages of documentation to the USA FDA for Emergency Use Authorization. We project a cost of <£10k for RELAVENT at a comfortable margin (compared to £20k-£70k for current ventilators). Note that RELAVENT provides fully invasive ventilator performance, unlike many of the "emergency use" designs that emerged in 2020.RELAVENT is elegantly designed with a relatively small number of easily sourced components, and can be inexpensively maintained.'''Please explain the longer term, future vision for the Company'''Dominance of the large, unaddressed market niche in NEE/LIMC. No additional investment should be required to reach initial target markets. Entry into air/land ambulance markets in High Income Countries. CAGR projected to be 9.4% for ICU market and 10% for emergency response/ambulance markets.'''Explain the core technologies and/or service propositions of your venture.'''Award-winning, high performance ICU ventilator. Affordable. Not limited by specialised supply chain issues. RELAVENT provides a long-term solution for ICU ventilation, unlike other emergency use ventilation devices developed in 2020 (e.g., “bag squeezers”). RELAVENT’S design features minimal moving parts, and has a projected usage of >100 million breaths before any component would need replacing.'''Does your commercial strategy rely on intellectual property assets?'''Yes. Imperial-owned IP. Patent is in PCT phase. UK office action did not identify major issues.'''What commercial progress have you made?'''Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.[[Category:Thesis]][[Category:Equities]]		RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.

			'''RELAVENT vision:'''

			To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).

			Note: Working title during development was JAMVENT.

			'''Status on current round:'''

			Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.

			<youtube>s9QnM3rjS14</youtube>

			==Investment Interview==

			'''Explain what your venture does.'''

			RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. Its operation requires minimal electrical power. RELAVENT can be run with an oxygen concentrator or bottled gases in case of challenges in hospital gas supplies.

			'''What stage is your business?'''

			Imperial College Spinout. TRL 4.

			'''Describe your advisers.'''

			Liz Hughes (CEO): High sales growth portfolio. Commercial effectiveness specialist, accredited leadership coach. Business growth and turnaround leader. Steve Atkinson (Board Chair): Successful 30-year career in medical devices, entrepreneur, experienced fund raiser, business leader. Multiple successful exits.

			'''Give an overview of your startup's financing history.'''

			Grants from Imperial College COVID fund (£60k) and Royal Academy of Engineering (£20k). Departmental support. Used for prototyping, testing and submission to USA FDA for Emergency Use Authorization.

			'''Explain the ownership structure of your company.'''

			Imperial-based Founders: van Batenburg-Sherwood, Mathiszig-Lee, Madekurozwa, Moore, Watson, Bonneuil, Frattolin. Imperial College (IP ownership; Founder-Driven Route).

			'''How many employees do you have?'''

			2.

			'''Please provide the name of a lawyer, who will represent you for the upcoming investment round.'''

			Taylor Wessing, Ross McNaughton.

			'''How much money are you seeking to raise in the current round?'''

			£3m.

			'''Do you have any existing commitments to the current round?'''

			Family offices tentatively committed for £2m but seeking lead investor.

			'''Explain why you are raising finance.'''

			Complete the regulatory-compliant design process (6-9 months). Submit applications for regulatory approval (2-3 months). Clinical testing (2-3 months). Marketing. Distribution.

			'''Please explain the history of your venture.'''

			RELAVENT aims to provide reliable ICU-standard ventilators to low income markets where current ventilator technologies are unaffordable. The project was initiated in March 2020 in response to the COVID-19 pandemic, but the market to address diseases such as TB, malaria and influenza is much larger. Within 72 days of project initiation, we had developed a working prototype, tested it to ISO standards and submitted several hundred pages of documentation to the USA FDA for Emergency Use Authorization. We project a cost of <£10k for RELAVENT at a comfortable margin (compared to £20k-£70k for current ventilators). Note that RELAVENT provides fully invasive ventilator performance, unlike many of the "emergency use" designs that emerged in 2020.

			RELAVENT is elegantly designed with a relatively small number of easily sourced components, and can be inexpensively maintained.

			'''Please explain the longer term, future vision for the Company'''

			Dominance of the large, unaddressed market niche in NEE/LIMC. No additional investment should be required to reach initial target markets. Entry into air/land ambulance markets in High Income Countries. CAGR projected to be 9.4% for ICU market and 10% for emergency response/ambulance markets.

			'''Explain the core technologies and/or service propositions of your venture.'''

			Award-winning, high performance ICU ventilator. Affordable. Not limited by specialised supply chain issues. RELAVENT provides a long-term solution for ICU ventilation, unlike other emergency use ventilation devices developed in 2020 (e.g., “bag squeezers”). RELAVENT’S design features minimal moving parts, and has a projected usage of >100 million breaths before any component would need replacing.

			'''Does your commercial strategy rely on intellectual property assets?'''

			Yes. Imperial-owned IP. Patent is in PCT phase. UK office action did not identify major issues.

			'''What commercial progress have you made?'''

			Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.
			[[Category:Thesis]]
			[[Category:Equities]]

109.180.50.163 at 23:19, 13 August 2022

2022-08-13T23:19:47Z

← Older revision		Revision as of 00:19, 14 August 2022
Line 1:		Line 1:
	~~'''About RELAVENT:'''~~		== Summary ==

	RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.		'''About RELAVENT:'''RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.'''RELAVENT vision:'''To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).Note: Working title during development was JAMVENT.'''Status on current round:'''Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.<youtube>s9QnM3rjS14</youtube>==Investment Interview=='''Explain what your venture does.'''RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. Its operation requires minimal electrical power. RELAVENT can be run with an oxygen concentrator or bottled gases in case of challenges in hospital gas supplies.'''What stage is your business?'''Imperial College Spinout. TRL 4.'''Describe your advisers.'''Liz Hughes (CEO): High sales growth portfolio. Commercial effectiveness specialist, accredited leadership coach. Business growth and turnaround leader. Steve Atkinson (Board Chair): Successful 30-year career in medical devices, entrepreneur, experienced fund raiser, business leader. Multiple successful exits.'''Give an overview of your startup's financing history.'''Grants from Imperial College COVID fund (£60k) and Royal Academy of Engineering (£20k). Departmental support. Used for prototyping, testing and submission to USA FDA for Emergency Use Authorization.'''Explain the ownership structure of your company.'''Imperial-based Founders: van Batenburg-Sherwood, Mathiszig-Lee, Madekurozwa, Moore, Watson, Bonneuil, Frattolin. Imperial College (IP ownership; Founder-Driven Route).'''How many employees do you have?'''2.'''Please provide the name of a lawyer, who will represent you for the upcoming investment round.'''Taylor Wessing, Ross McNaughton.'''How much money are you seeking to raise in the current round?'''£3m.'''Do you have any existing commitments to the current round?'''Family offices tentatively committed for £2m but seeking lead investor.'''Explain why you are raising finance.'''Complete the regulatory-compliant design process (6-9 months). Submit applications for regulatory approval (2-3 months). Clinical testing (2-3 months). Marketing. Distribution.'''Please explain the history of your venture.'''RELAVENT aims to provide reliable ICU-standard ventilators to low income markets where current ventilator technologies are unaffordable. The project was initiated in March 2020 in response to the COVID-19 pandemic, but the market to address diseases such as TB, malaria and influenza is much larger. Within 72 days of project initiation, we had developed a working prototype, tested it to ISO standards and submitted several hundred pages of documentation to the USA FDA for Emergency Use Authorization. We project a cost of <£10k for RELAVENT at a comfortable margin (compared to £20k-£70k for current ventilators). Note that RELAVENT provides fully invasive ventilator performance, unlike many of the "emergency use" designs that emerged in 2020.RELAVENT is elegantly designed with a relatively small number of easily sourced components, and can be inexpensively maintained.'''Please explain the longer term, future vision for the Company'''Dominance of the large, unaddressed market niche in NEE/LIMC. No additional investment should be required to reach initial target markets. Entry into air/land ambulance markets in High Income Countries. CAGR projected to be 9.4% for ICU market and 10% for emergency response/ambulance markets.'''Explain the core technologies and/or service propositions of your venture.'''Award-winning, high performance ICU ventilator. Affordable. Not limited by specialised supply chain issues. RELAVENT provides a long-term solution for ICU ventilation, unlike other emergency use ventilation devices developed in 2020 (e.g., “bag squeezers”). RELAVENT’S design features minimal moving parts, and has a projected usage of >100 million breaths before any component would need replacing.'''Does your commercial strategy rely on intellectual property assets?'''Yes. Imperial-owned IP. Patent is in PCT phase. UK office action did not identify major issues.'''What commercial progress have you made?'''Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.[[Category:Thesis]][[Category:Equities]]

	'''RELAVENT vision:'''

	To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).

	Note: Working title during development was JAMVENT.

	'''Status on current round:'''

	Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.

	<youtube>s9QnM3rjS14</youtube>

	==Investment Interview==

	'''Explain what your venture does.'''

	RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. Its operation requires minimal electrical power. RELAVENT can be run with an oxygen concentrator or bottled gases in case of challenges in hospital gas supplies.

	'''What stage is your business?'''

	Imperial College Spinout. TRL 4.

	'''Describe your advisers.'''

	Liz Hughes (CEO): High sales growth portfolio. Commercial effectiveness specialist, accredited leadership coach. Business growth and turnaround leader. Steve Atkinson (Board Chair): Successful 30-year career in medical devices, entrepreneur, experienced fund raiser, business leader. Multiple successful exits.

	'''Give an overview of your startup's financing history.'''

	Grants from Imperial College COVID fund (£60k) and Royal Academy of Engineering (£20k). Departmental support. Used for prototyping, testing and submission to USA FDA for Emergency Use Authorization.

	'''Explain the ownership structure of your company.'''

	Imperial-based Founders: van Batenburg-Sherwood, Mathiszig-Lee, Madekurozwa, Moore, Watson, Bonneuil, Frattolin. Imperial College (IP ownership; Founder-Driven Route).

	'''How many employees do you have?'''

	2.

	'''Please provide the name of a lawyer, who will represent you for the upcoming investment round.'''

	Taylor Wessing, Ross McNaughton.

	'''How much money are you seeking to raise in the current round?'''

	£3m.

	'''Do you have any existing commitments to the current round?'''

	Family offices tentatively committed for £2m but seeking lead investor.

	'''Explain why you are raising finance.'''

	Complete the regulatory-compliant design process (6-9 months). Submit applications for regulatory approval (2-3 months). Clinical testing (2-3 months). Marketing. Distribution.

	'''Please explain the history of your venture.'''

	RELAVENT aims to provide reliable ICU-standard ventilators to low income markets where current ventilator technologies are unaffordable. The project was initiated in March 2020 in response to the COVID-19 pandemic, but the market to address diseases such as TB, malaria and influenza is much larger. Within 72 days of project initiation, we had developed a working prototype, tested it to ISO standards and submitted several hundred pages of documentation to the USA FDA for Emergency Use Authorization. We project a cost of <£10k for RELAVENT at a comfortable margin (compared to £20k-£70k for current ventilators). Note that RELAVENT provides fully invasive ventilator performance, unlike many of the "emergency use" designs that emerged in 2020.

	RELAVENT is elegantly designed with a relatively small number of easily sourced components, and can be inexpensively maintained.

	'''Please explain the longer term, future vision for the Company'''

	Dominance of the large, unaddressed market niche in NEE/LIMC. No additional investment should be required to reach initial target markets. Entry into air/land ambulance markets in High Income Countries. CAGR projected to be 9.4% for ICU market and 10% for emergency response/ambulance markets.

	'''Explain the core technologies and/or service propositions of your venture.'''

	Award-winning, high performance ICU ventilator. Affordable. Not limited by specialised supply chain issues. RELAVENT provides a long-term solution for ICU ventilation, unlike other emergency use ventilation devices developed in 2020 (e.g., “bag squeezers”). RELAVENT’S design features minimal moving parts, and has a projected usage of >100 million breaths before any component would need replacing.

	'''Does your commercial strategy rely on intellectual property assets?'''

	Yes. Imperial-owned IP. Patent is in PCT phase. UK office action did not identify major issues.

	'''What commercial progress have you made?'''

	Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.
	[[Category:Thesis]]
	[[Category:Equities]]

>Louis at 17:16, 22 July 2022

2022-07-22T17:16:37Z

← Older revision		Revision as of 18:16, 22 July 2022
Line 78:		Line 78:

	Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.		Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.
			[[Category:Thesis]]
			[[Category:Equities]]

172.18.0.3 at 15:31, 17 May 2022

2022-05-17T15:31:03Z

← Older revision		Revision as of 16:31, 17 May 2022
Line 13:		Line 13:
	Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.		Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.

	<~~html~~>		<youtube>s9QnM3rjS14</youtube>
	<~~iframe width="560" height="315" src="https:/~~/~~www.~~youtube~~.com/embed/s9QnM3rjS14" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>~~
	~~</html~~>

	==Investment Interview==		==Investment Interview==

>Sarah: Created page with "'''About RELAVENT:''' RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies. '''RELAVENT vision:''' To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly..."

2022-03-06T13:18:57Z

Created page with "'''About RELAVENT:''' RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies. '''RELAVENT vision:''' To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly..."

New page

'''About RELAVENT:'''

RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. RELAVENT is designed for robustness, easy maintenance, intuitive operation, and operates efficiently with low capacity gas supplies.

'''RELAVENT vision:'''

To become the go-to ventilation product for the large unmet need for ICU ventilators in Newly Emerging Economies (NEE) and Low-Middle Income Countries (LMIC).

Note: Working title during development was JAMVENT.

'''Status on current round:'''

Seeking to raise £3m for a 24-month runway to reach target market, of which £2m is tentatively committed.

<html>
<iframe width="560" height="315" src="https://www.youtube.com/embed/s9QnM3rjS14" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
</html>

==Investment Interview==

'''Explain what your venture does.'''

RELAVENT provides high-performance, low-cost ICU ventilators for the NEE/LMIC, ambulance and paediatric markets without relying on supply chains for specialised components used in current ventilators. Its operation requires minimal electrical power. RELAVENT can be run with an oxygen concentrator or bottled gases in case of challenges in hospital gas supplies.

'''What stage is your business?'''

Imperial College Spinout. TRL 4.

'''Describe your advisers.'''

Liz Hughes (CEO): High sales growth portfolio. Commercial effectiveness specialist, accredited leadership coach. Business growth and turnaround leader. Steve Atkinson (Board Chair): Successful 30-year career in medical devices, entrepreneur, experienced fund raiser, business leader. Multiple successful exits.

'''Give an overview of your startup's financing history.'''

Grants from Imperial College COVID fund (£60k) and Royal Academy of Engineering (£20k). Departmental support. Used for prototyping, testing and submission to USA FDA for Emergency Use Authorization.

'''Explain the ownership structure of your company.'''

Imperial-based Founders: van Batenburg-Sherwood, Mathiszig-Lee, Madekurozwa, Moore, Watson, Bonneuil, Frattolin. Imperial College (IP ownership; Founder-Driven Route).

'''How many employees do you have?'''

2.

'''Please provide the name of a lawyer, who will represent you for the upcoming investment round.'''

Taylor Wessing, Ross McNaughton.

'''How much money are you seeking to raise in the current round?'''

£3m.

'''Do you have any existing commitments to the current round?'''

Family offices tentatively committed for £2m but seeking lead investor.

'''Explain why you are raising finance.'''

Complete the regulatory-compliant design process (6-9 months). Submit applications for regulatory approval (2-3 months). Clinical testing (2-3 months). Marketing. Distribution.

'''Please explain the history of your venture.'''

RELAVENT aims to provide reliable ICU-standard ventilators to low income markets where current ventilator technologies are unaffordable. The project was initiated in March 2020 in response to the COVID-19 pandemic, but the market to address diseases such as TB, malaria and influenza is much larger. Within 72 days of project initiation, we had developed a working prototype, tested it to ISO standards and submitted several hundred pages of documentation to the USA FDA for Emergency Use Authorization. We project a cost of <£10k for RELAVENT at a comfortable margin (compared to £20k-£70k for current ventilators). Note that RELAVENT provides fully invasive ventilator performance, unlike many of the "emergency use" designs that emerged in 2020.

RELAVENT is elegantly designed with a relatively small number of easily sourced components, and can be inexpensively maintained.

'''Please explain the longer term, future vision for the Company'''

Dominance of the large, unaddressed market niche in NEE/LIMC. No additional investment should be required to reach initial target markets. Entry into air/land ambulance markets in High Income Countries. CAGR projected to be 9.4% for ICU market and 10% for emergency response/ambulance markets.

'''Explain the core technologies and/or service propositions of your venture.'''

Award-winning, high performance ICU ventilator. Affordable. Not limited by specialised supply chain issues. RELAVENT provides a long-term solution for ICU ventilation, unlike other emergency use ventilation devices developed in 2020 (e.g., “bag squeezers”). RELAVENT’S design features minimal moving parts, and has a projected usage of >100 million breaths before any component would need replacing.

'''Does your commercial strategy rely on intellectual property assets?'''

Yes. Imperial-owned IP. Patent is in PCT phase. UK office action did not identify major issues.

'''What commercial progress have you made?'''

Business plan in place. Full financials available on request. Partnerships with two medical device design firms (one in the UK and one in India) are in place to complete regulatory-compliant design processes.